BTC $61,959.90 −3.24%ETH $1,754.72 −3.37%SOL $71.40 −5.09%S&P 500 7,175.83 −2.02%Nasdaq 100 26,517.00 −2.21%Gold $3,571.40 −3.73%Brent $88.97 −1.70%EUR/USD 1.0990 −0.06%DXY 103.66 −0.06%US10Y 4.98% −1.46%NVDA $145.98 −3.30%TSLA $374.41 −2.43%
FREEKONOMIST
WorldLaunched

vVardis IPO prices at $18, below its $21 to $24 range

vVardis IPO: the Swiss dental company priced its New York listing at $18 a share, below the $21 to $24 range it planned, and raises about $175 million.

Event: November 13, 2026
Primary source: November 13, 2026
Published here: November 14, 2026 at 12:07 PM UTC
Read: 3 min

What happened

vVARDIS Holding AG, a dental company from Zug, Switzerland, priced its IPO at $18.00 per Class A share. The offering is 9,722,223 shares, which raises about $175 million. The planned range was $21 to $24. Trading on the NYSE under the ticker VVVV was due to start on November 13. Closing is expected on or about November 16.

Why it matters to you

The price landed below the range, and the company still loses money: a $27.8 million net loss in the first half of 2026, according to blue News. The targeted market value fell from up to $4.37 billion to about $3.28 billion.

What to check and watch

Whether the deal closes on schedule and whether the underwriters use their option for 1,458,333 more shares. For trading, check a live market page. This is not investment advice.

Where it’s happening

LIVE

Drag to spin. Green dots: the exchange is trading right now (regular hours, holidays not counted). Shadow: where it is night now. Borders: Natural Earth, quakes: USGS. Layer idea: God’s Eye View (MIT).

Flights: what adsb.lol volunteer ADS-B receivers see right now (ODbL), refreshed every minute. Few receivers over oceans and remote land; military and private jets are often hidden.

What was announced. On November 13, 2026, vVARDIS Holding AG said it priced its initial public offering at $18.00 per Class A ordinary share. The deal covers 9,722,223 shares. The underwriters can buy up to 1,458,333 more within 30 days. The shares were expected to start trading on the New York Stock Exchange that day under the symbol VVVV. Closing is expected on or about November 16.

Price against plan. On November 6, Renaissance Capital reported planned terms: about 9.5 million shares at $21 to $24, to raise $214 million. The final price is below that range. blue News says the deal brings in about $175 million and that the targeted market capitalization fell from up to $4.37 billion to about $3.28 billion. Renaissance Capital put the value at $1.3 billion at the midpoint of the old range. The sources do not explain how each figure is counted, so treat them as separate measures.

The company. vVardis, from Zug, was founded in 2020. Its Curodont treatment for early-stage cavities is peptide-based and applied in a dental office in five minutes or less, with no drilling or needles. In the US it sells only through Henry Schein, and its US product brings most of the revenue. Revenue was $50 million for the 12 months ended June 30, 2026. The founders are the sisters Haley and Goly Abivardi, known from the dental chain Swiss Smile.

The numbers behind the price. The company is growing but still loses money. In the first half of 2026 it reported a net loss of $27.8 million and an operating cash outflow of $16.3 million. Last year's loss was $56.4 million, according to swissinfo. At the end of 2025 it had loans of $103 million, with interest of up to 16% on part of the debt. Repayments fall due in 2027 and 2030.

Who keeps control. The founders plan to stay in charge. Swissinfo says their higher-voting shares give them 87% of the voting rights. Swissinfo notes that outside shareholders share the risk while the sisters keep full control of the company's direction.

What you can do. If you follow IPOs, read the final prospectus on the SEC website and its risk factors, not only the headlines. We do not report first-day trading figures: the pages we could open were not consistent. This is not advice to buy or sell.

Confirmed facts

  • vVARDIS Holding AG priced its initial public offering of 9,722,223 Class A ordinary shares at $18.00 per share.[1][2]
  • The underwriters have a 30-day option to buy up to 1,458,333 more Class A shares at the IPO price.[1][2]
  • The shares were expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol VVVV.[1][2]
  • Closing of the offering is expected on or about November 16, 2026, subject to customary conditions.[1]
  • Goldman Sachs and J.P. Morgan are the joint bookrunning managers; William Blair, UBS Investment Bank and Deutsche Bank Securities are bookrunners.[1]
  • The registration statement on Form F-1 was declared effective by the US Securities and Exchange Commission on November 12, 2026.[1]
  • A price range of $21 to $24 had been planned.[2][4]
  • blue News says the offering brings in about $175 million.[2]
  • blue News says the targeted market capitalization fell from an initial estimate of up to $4.37 billion to about $3.28 billion.[2]
  • On November 6, Renaissance Capital reported planned terms of about 9.5 million shares at $21 to $24, to raise $214 million, with a market value of $1.3 billion at the midpoint of the range.[4]
  • vVardis was founded in 2020 and treats tooth decay without drilling.[2][4]
  • Its Curodont treatment for early-stage cavities is peptide-based and applied in a dental office in five minutes or less, with no drilling or needles.[4]
  • In the US, the company sells exclusively through Henry Schein, and its US product generates the vast majority of revenue.[4]
  • vVardis booked $50 million in revenue for the 12 months ended June 30, 2026.[4]
  • In the first half of 2026 the company reported a net loss of $27.8 million and a cash outflow of $16.3 million from operating activities.[2]
  • Last year's loss was $56.4 million, according to swissinfo.[3]
  • At the end of 2025 vVardis had outstanding loans of $103 million, with interest of up to 16% on part of the debt, due for repayment in 2027 and 2030.[3]
  • Founders Haley and Goly Abivardi intend to keep control after the IPO; swissinfo says their higher-voting shares give them 87% of the voting rights.[2][3]
  • About 95% of vVardis revenue comes from the US and 2% from Switzerland.[3]

Implications

  • ConfirmedThe IPO priced below the planned range, so the company raises about $175 million instead of the $214 million planned in the early terms.
  • Our readingWith losses and loans due in 2027 and 2030, the company depends on continued growth or new funding. This is our reading of the figures, not a forecast.

Still unknown

  • How the shares traded on the first day. The page we opened that cites numbers is not consistent, so we leave them out.
  • How the valuation is counted: Renaissance Capital gave $1.3 billion at the midpoint of the range, blue News gave about $3.28 billion at the final price.
  • Whether the underwriters will use their option for 1,458,333 more shares.
  • How much of the proceeds will go to repay debt. The pages we opened do not say.

Who it affects

Switzerland, US, World. People who follow IPOs, readers interested in Swiss companies and healthcare stocks

Sources

  1. Business Wire (via Yahoo Finance): vVARDIS Announces Pricing of Initial Public Offering November 13, 2026 · official
  2. blue News (Keystone-SDA): Vvardis is going public on the U.S. stock market at a lower price than planned November 13, 2026 · media
  3. SWI swissinfo.ch (SRF): 'Swiss Smile' sisters set sights on multi-billion-dollar IPO on Wall Street November 13, 2026 · media
  4. Renaissance Capital: Cavity treatment provider vVardis sets terms for $214 million US IPO November 6, 2026 · media
Cover as an image
Did this make it clearer?

Cover: Freekonomist graphic, a symbolic image, not a photo of the event. This is a news explainer, not financial advice.

More stories

Get it first on TelegramFed, jobs, inflation and big crypto moves land in the channel minutes after release. Plus a daily poll: higher or lower?Join

Morning brief by email

The night's key moves and what matters today, in 2 minutes. One-click unsubscribe.

By tapping Subscribe you agree to receive Freekonomist emails and accept the data policy.

BloFinBloFinAd · partner

Reading about markets? Try it yourself

A crypto futures exchange. Start with a small amount and low leverage: the easiest way to learn the market without extra risk.

Affiliate link: if you sign up, we may get paid. Ads never affect our exchange rating or news. Leveraged futures are high risk: you can lose everything you put in, and chasing volume for a prize adds fees and risk. 18+ only.